Analyst Price Targets — VCEL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 15, 2026 12:45 pm | — | Truist Financial | $42.00 | $35.21 | TheFly | Vericel price target lowered to $42 from $48 at Truist |
| March 10, 2026 7:55 pm | Mike Kratky | Leerink Partners | $46.00 | $33.40 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Vericel Corporation (VCEL) following conference |
| December 18, 2025 2:16 pm | Richard Newitter | Truist Financial | $45.00 | $36.42 | TheFly | Vericel price target lowered to $45 from $50 at Truist |
| October 15, 2025 12:48 pm | — | Truist Financial | $41.00 | $34.50 | TheFly | Vericel price target lowered to $41 from $46 at Truist |
| December 18, 2024 12:32 pm | Richard Newitter | Truist Financial | $67.00 | $56.25 | TheFly | Vericel price target raised to $67 from $61 at Truist |
| August 26, 2024 9:33 am | Ryan Zimmerman | BTIG | $55.00 | $50.05 | StreetInsider | BTIG Reiterates Buy Rating on Vericel Corporation (VCEL) |
| August 2, 2024 6:07 am | Swayampakula Ramakanth | H.C. Wainwright | $60.00 | $47.52 | TheFly | Vericel price target raised to $60 from $55 at H.C. Wainwright |
| July 16, 2024 9:46 am | Richard Newitter | Truist Financial | $57.00 | $52.10 | TheFly | Vericel price target raised to $57 from $56 at Truist |
| July 5, 2024 10:09 am | Ryan Zimmerman | BTIG | $56.00 | $46.68 | StreetInsider | BTIG Reiterates Buy Rating on Vericel Corporation (VCEL) |
| January 25, 2024 6:02 am | Samuel Brodovsky | Truist Financial | $51.00 | $42.60 | StreetInsider | Truist Securities Upgrades Vericel Corporation (VCEL) to Buy |
Latest News for VCEL
Aberdeen Group plc boosted its holdings in Vericel Corporation (NASDAQ: VCEL) by 7.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 583,884 shares of the biotechnology company's stock after purchasing an additional 41,018 shares during the quarter. Aberdeen Group
Shares of Vericel Corporation (NASDAQ: VCEL - Get Free Report) have earned an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of…
Congress Asset Management Co. grew its holdings in shares of Vericel Corporation (NASDAQ: VCEL) by 11.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,664,578 shares of the biotechnology company's stock after purchasing an additional 169,971 shares during the period. Congress Asset Management
Intech Investment Management LLC decreased its stake in shares of Vericel Corporation (NASDAQ: VCEL) by 42.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,887 shares of the biotechnology company's stock after selling 23,142 shares during the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VCEL.
U.S. House Trading
No House trades found for VCEL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.